UNITED THERAPEUTICS Corp
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
UTHR$582.46+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In millions, except per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| (Unaudited) | ||
| Total revenues | $781.5 | $794.4 |
| Operating expenses: | ||
| Cost of sales | 133.4 | 92.5 |
| Research and development | 138.2 | 149.0 |
| Selling, general, and administrative | 184.1 | 170.1 |
| Total operating expenses | 455.7 | 411.6 |
| Operating income | 325.8 | 382.8 |
| Interest income | 41.8 | 51.1 |
| Interest expense | (3.0) | (6.1) |
| Other expense, net | (46.3) | (4.3) |
| Total other (expense) income, net | (7.5) | 40.7 |
| Income before income taxes | 318.3 | 423.5 |
| Income tax expense | (43.4) | (101.3) |
| Net income | $274.9 | $322.2 |
| Net income per common share: | ||
| Basic | $6.32 | $7.18 |
| Diluted | $5.82 | $6.63 |
| Weighted average number of common shares outstanding: | ||
| Basic | 43.5 | 44.9 |
| Diluted | 47.2 | 48.6 |
| 4 | United Therapeutics, a public benefit corporation |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.